HBK Investments’s ProKidney PROK Stock Holding History

HBK Investments’s Portfolio PROK Stock Details PROK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-400,000	Closed	-$4M	–	499
2022 Q2	$4M	Hold	400,000	–	–	0.02%	256
2022 Q1	$3.96M	Hold	400,000	–	–	0.02%	299
2021 Q4	$3.96M	Hold	400,000	–	–	0.01%	304
2021 Q3	$3.92M	Hold	400,000	–	–	0.02%	311
2021 Q2	$4.04M	Buy	+400,000	New	+$4.04M	0.01%	347

Other funds holding PROK

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

MCM

Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

HBK Investments's PROK Position: Q3 2022 in Review

HBK Investments sold out of ProKidney (PROK) in Q3 2022, closing a stake of 400,000 shares — an estimated $4M sold.

HBK Investments first reported a position in PROK in Q2 2021 and held it in 5 quarters. The position peaked at $4.04M in Q2 2021. 18 funds tracked by Wall St. Rank hold PROK as of Q3 2022.

HBK Investments reported no remaining ProKidney position as of Q3 2022 after selling out during the quarter.
HBK Investments sold 400,000 ProKidney shares in Q3 2022, an estimated $4M.
HBK Investments first reported a position in ProKidney in Q2 2021 and held it in 5 quarters.
HBK Investments's ProKidney position peaked at $4.04M in Q2 2021.
18 funds tracked by Wall St. Rank held ProKidney as of Q3 2022.

Based on HBK Investments's 13F filing for Q3 2022, filed 14 Nov 2022.